HIGHLIGHTS
- who: Raquel Alves and collaborators from the Laboratory of and Hematology (LOH) and University Clinic of Hematology, Faculty of Medicine have published the article: Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia, in the Journal: Biomedicines 2022, 10, 1158. of /2022/
- what: The authors evaluate the therapeutic potential of a P-glycoprotein and BCRP inhibitor elacridar in sensitive (K562 and LAMA-84) and imatinib-resistant (K562-RC and K562-RD) CML cell lines as monotherapy and combined with imatinib. In further studies, the authors focus on imatinib . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.